Journal of Nanobiotechnology · 2022 · 17 citations · 33 references
Life SciencesBiophysicsPharmacologyCell SignalingInflammationSignal TransductionAcute Respiratory Distress SyndromeCell-nanoparticle InteractionsEndothelial ActivationNanomaterials For Drug DeliveryNanomedicinePulmonary PermeationBarrier Permeability RegulationInflammasome RegulationInflammasome ResponsesMembrane HyperpolarizationOsmotic PressureProtein Osmotic PressurePulmonary PermeabilityTransmembrane Pressure
Acute respiratory distress syndrome (ARDS), caused by noncardiogenic pulmonary edema (PE), contributes significantly to Coronavirus 2019 (COVID-19)-associated morbidity and mortality. We explored the effect of transmembrane osmotic pressure (OP) gradients in PE using a fluorescence resonance energy transfer-based Intermediate filament (IF) tension optical probe. Angiotensin-II- and bradykinin-induced increases in intracellular protein nanoparticle (PN)-OP were associated with inflammasome production and cytoskeletal depolymerization. Intracellular protein nanoparticle production also resulted in cytomembrane hyperpolarization and L-VGCC-induced calcium signals, which differed from diacylglycerol-induced calcium increment via TRPC6 activation. Both pathways involve voltage-dependent cation influx and OP upregulation via SUR1-TRPM4 channels. Meanwhile, intra/extracellular PN-induced OP gradients across membranes upregulated pulmonary endothelial and alveolar barrier permeability. Attenuation of intracellular PN, calcium signals, and cation influx by drug combinations effectively relieved intracellular OP and pulmonary endothelial nonselective permeability, and improved epithelial fluid absorption and PE. Thus, PN-OP is pivotal in pulmonary edema in ARDS and COVID-19, and transmembrane OP recovery could be used to treat pulmonary edema and develop new drug targets in pulmonary injury.
33
Functional Significance of Cell Volume Regulatory Mechanisms
Florian Läng, Gillian L. Busch, Markus Ritter et al. · Physiological Reviews · 1998 · 1.9K citations
Tranilast directly targets NLRP3 to treat inflammasome‐driven diseases
Yi Huang, Hua Jiang, Yun Chen et al. · EMBO Molecular Medicine · 2018 · 501 citations · Full text
TRPC3 and TRPC6 are essential for angiotensin II‐induced cardiac hypertrophy
Naoya Onohara, Motohiro Nishida, Ryuji Inoue et al. · The EMBO Journal · 2006 · 416 citations · Full text